Nasdaq Approves Listing for Post-Merger Coeptis Stock, Merger Expected Q2 2026
Nasdaq approved the listing application for Coeptis Therapeutics’ post-merger common stock under the symbol “ZSQR” upon satisfaction of key closing conditions including Form S-4 effectiveness and shareholder approval. The merger remains subject to remaining customary closing conditions and is expected to complete in Q2 2026.
1. Listing Approval and Key Conditions Satisfied
Nasdaq has approved the listing application for the combined company’s common stock under the symbol “ZSQR”, fulfilling a critical merger closing condition that followed the effectiveness of the Form S-4 registration statement and stockholder approval at the January 30 meeting.
2. Merger Structure and Timeline
The pending transaction will make Z Squared, Inc. a wholly owned subsidiary of Coeptis Therapeutics, and the corporate name will change to Z Squared Inc. The deal remains subject to customary closing conditions and is slated to close in the second quarter of 2026.
3. Post-Merger Operations and Assets
Upon closing, Z Squared will deploy 9,800 ASIC miners across North Carolina, South Carolina and Iowa to secure Dogecoin and Litecoin networks, converting mined digital assets to U.S. dollars or stablecoins typically within 24 hours under a cash-flow-focused strategy.